Close Menu

services alliance

Using Revel Health's health action platform, the partners will communicate and promote CLS's genetic testing offering to Medicare Advantage members.

The Carlsbad, California-based company said that the contract — its third with the EPA — has a potential value of $25 million over five years.

The deal includes integrating an online ordering process for Ambry's genetic tests into Volpara's Aspen Breast software for medical practice management.

The companies will bundle claims analytics, clinical decision support, provider education, and other pharmacist-driven support for prescribers.

The companies have agreed to combine their respective offerings into a single services package for drug target identification and validation.

Saga has developed a digital PCR-based technology that it says can detect circulating tumor DNA with a mutational allele frequency of 0.001 percent.

Illumina, Twist Bioscience, and DNA Script are among the private sector collaborators of the groups receiving funds to develop technology platforms.

The deal provides whole-genome sequencing for patients with rare diseases or cancer and could make sequencing part of the standard of care for NHS England.

The companies had agreed in early 2018 to collaborate on the development of technologies to support precision oncology initiatives, but Roche said "priorities" have changed.

The Diagenode services will utilize Bio-Rad's ddSEQ Single-Cell Isolator to encapsulate thousands of cell nuclei or whole cells into nanoliter-sized droplets.

Pages

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.